COLORADO SPRINGS, Colo.--(Business Wire)--
Cannabis Science Hails The American Medical Association For Urging The United
States To Facilitate Clinical Research and Development of Cannabinoid-Based
Medicines Which Validates The Company`s Strategy To Produce Critically Important
FDA Approved Cannabinoid-Based Medicines For Patients
Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis
company, is hailing the call by the American Medical Association's House of
Delegates for "marijuana's status as a federal Schedule I controlled substance
be reviewed with the goal of facilitating the conduct of clinical research and
development of cannabinoid-based medicines."
Richard Cowan, Cannabis Science CFO, noted, "The AMA has officially joined the
other medical groups in their recognition of the medical value of cannabis. Last
year, the American College of Physicians also called for a reclassification of
cannabis' Schedule I status. Previously, many other health organizations,
including the American Nurses Association and the American Public Health
Association, have called for the legal recognition of medical cannabis."
Under federal law, all substances in Schedule I are defined as possessing "no
currently accepted use in treatment in the United States" and also having a high
potential for abuse. In 1970 Congress classified marijuana, and all of the
cannabinoids (even those with no psychoactive properties) as Schedule I
substances upon passage of the Controlled Substances Act. This classification
was supposed to be temporary, but blocking research kept it in Schedule I.
Dr. Robert Melamede, PhD., Cannabis Science Inc. President and CEO, stated, "It
is now clear that the AMA has embraced the plethora of peer reviewed science
supporting the medical applications of the cannabis plant. Their call for the US
to facilitate `research and development of cannabinoid-based medicines` is an
important validation of our company`s strategy and should make it much easier
for us to develop and market products that will help patients. Most people would
be shocked to know that the federal government has actually been blocking
research on the medical benefits of cannabis while supporting research aimed at
demonstrating the negatives. Now that the AMA has embraced this modern science,
and President Obama has created new Federal policies and guidelines, the Federal
Government can no longer ignore the importance of cannabinoid-based medicines."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and
development. The Company works with world authorities on phytocannabinoid
science targeting critical illnesses, and adheres to scientific methodologies to
develop, produce, and commercialize phytocannabinoid-based pharmaceutical
products. In sum, we are dedicated to the creation of cannabis-based medicines,
both with and without psychoactive properties, to treat disease and the symptoms
of disease, as well as for general health maintenance.
This Press Release includes forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act
of 1934. A statement containing works such as "anticipate," "seek," intend,"
"believe," "plan," "estimate," "expect," "project," "plan," or similar phrases
may be deemed "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events or results
anticipated by these forward-looking statements may not occur. Factors that
could cause or contribute to such differences include the future U.S. and global
economies, the impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc. does not undertake any duty nor does it intend to update the
results of these forward-looking statements.
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
info@cannabisscience.com
www.cannabisscience.com
or
Peter Glaser, 1-888-889-0888
Investor Relations
info@cannabisscience.com
www.cannabisscience.com
Copyright Business Wire 2009
